Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2020

View Archived Issues

Targeting GCGR signaling pathway counteracts PI3K inhibitor-induced hyperglycemia

DISC-0974 decreases hepcidin and increases transferrin saturation in inflammation models

First-in-human data presented for talquetamab in patients with RRMM

Results of RCT evaluating nilotinib in patients with moderately advanced Parkinson's disease

DISC-A demonstrates efficacy in low hepcidin rat model

CTPS2 as novel prognostic biomarker in CLL

FDA lifts clinical hold on ASPIRO study of AT-132

Orelabrutinib approved in China for two cancer indications

Shanghai Institute of Materia Medica, Fudan University patent PD-1/PD-L1 interaction inhibitors

First subject dosed in phase I study of ASC-42

National Institute of Pharmaceutical R&D describes M3 antagonists/beta2-adrenoceptor agonists

New autotaxin inhibitors described by Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical

Medshine Discovery synthesizes new JAK1/JAK2 inhibitors

New ERK inhibitors discovered at Hutchison MediPharma

Byvasda approved in China the treatment of recurrent glioblastoma

Arctic Vision obtains IND approval for ARVN-001 in China

NX-2127 shows promising antitumor activity in models of B-cell malignancies

Enrollment ongoing in phase II study of PHA-022121

Nociceptive neurons shown to boost hematopoiesis

Geron initiates phase III study of imetelstat in myelofibrosis refractory to JAK inhibitors

ZyCoV-D vaccine candidate demonstrates safety and immunogenicity in phase I/II study

Primary endpoint not met in phase III trial of eprenetapopt in TP53-mutant myelodysplastic syndromes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...